Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a histologically confirmed diagnosis of squamous cell carcinoma, operable or inoperable tumors, stage III (T3N0-1) and IVA-B (T1-4 N2-3M0 or T4N0-1M0) of oral cavity, oropharynx, hypopharynx and larynx. For patients with oropharynx primary, either HPV negative or HPV positive with a \> 10 pack year tobacco history or current smokers are eligible. HPV status should be determined before the enrollment in only non-smokers with oropharynx primary by HPV in-situ hybridization and/or p16 immunostain.~2. Patients must have measurable disease of primary, nodes or both by clinical and radiographic methods per RECIST v1.1..~3. No prior therapy, including surgery with curative intent, chemotherapy, radiation therapy, immunotherapy, EGFR targeted therapies, or any other investigational agents.~4. Age \>= 18 years.~5. ECOG performance status 0-1.~6. Patients must have normal hepatic, renal and bone marrow function.~   * Absolute neutrophil count \>=1,000/ mm3 Count~  * Platelets \>= 100,000/mm3 Count~  * Total serum bilirubin =\< 1.5mg/dL Level:~  * AST and ALT =\< 2.5 X ULN~  * Alkaline Phosphatase =\< 2.5 X ULN~  * Total calculated creatinine clearance \>= 60 mL/min~7. Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer.~8. Patients with the following within the last 6 months prior to pre-registration must be evaluated by a cardiologist and/or neurologist prior to entry into the study.~   * Congestive heart failure \> NYHA Class II~  * CVA/TIA~  * Unstable angina~  * Myocardial infarction (with or without ST elevation)~9. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Any prior radiation above the clavicles.~2. Any prior invasive malignancy (unless non-melanomatous resectable skin or the DFS is 2 years or more).~3. History of allergic reactions attributed to compounds of similar chemical or biological composition to afatinib, or other agents used in study.~4. Cardiac left ventricular dysfunction with resting ejection fraction of less than institutional lower limit of normal ( if no lower limit of normal is defined in the institution, the lower limit is 50%)~5. Gastrointestinal tract disease resulting in an inability to take or absorb oral or enteral medication.~6. Baseline significant gastrointestinal symptoms with diarrhoea as a major symptom or a CTCAE Grade \>1 diarrhoea of any etiology.~7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~8. Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception.~9. Known pre-existing interstitial lung disease (ILD)~10. Pregnant women are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Arm (Type: EXPERIMENTAL): Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam. After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV. Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC. The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT.

Based on this trial design, predict the completion outcome and termination type (if applicable).